Paul Hastings Advises Redmile in Series A for One Biosciences
Deal News | Aug 04, 2025 | Paul Hastings
Paul Hastings LLP represented Redmile in a Series A fundraising round for One Biosciences, a pioneering biotech firm focused on precision oncology. The capital raised will expedite the company’s single-cell tumor transcriptomic profiling platform, bringing precision medicine closer to clinical application. The financing also aims to form strategic alliances with pharmaceutical and biotechnology corporations looking to incorporate OneCure, One Biosciences' proprietary technology, into their drug development and clinical trials. The advisory team from Paul Hastings was led by Private Equity partner Sébastien Crépy.
Sectors
- Biotechnology
- Private Equity
Geography
- United States – Paul Hastings LLP, the advisor in the transaction, is headquartered in the U.S.
Industry
- Biotechnology – The article focuses on biotechnology as One Biosciences is a company in this sector, specializing in precision oncology technologies.
- Private Equity – Redmile's involvement in the fundraising round represents activity within the private equity sector.
Financials
- Series A Fundraising – The financial activity discussed, enabling One Biosciences to develop its technology and partnerships.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Paul Hastings LLP | Advisor | Company | Legal advisor providing services to Redmile in the fundraising round. |
| Redmile | Investor | Company | Participated in the Series A funding round for One Biosciences. |
| One Biosciences | Target Company | Company | A biotech firm focused on precision oncology and advanced tumor profiling technology. |